AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29864379 — intervention group
Group type: COMPARATOR
Intervention: Dacomitinib vs Gefitinib
Number of subjects: 452
Study 27138789 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D (≥30 ng/mL)
Number of subjects: 0
Study 27138789 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D
Number of subjects: 0
Study 27138789 — intervention group
Group type: COMPARATOR
Intervention: UDCA
Number of subjects: 0
Study 25132143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of 400 mg oral zinc sulfate with podophyllin
Number of subjects: 228
Study 25132143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of 400 mg oral zinc sulfate with imiquimod
Number of subjects: 228
Study 25132143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of 400 mg oral zinc sulfate with cryotherapy
Number of subjects: 228
Study 25132143 — intervention group
Group type: COMPARATOR
Intervention: Podophyllin alone
Number of subjects: 228
Study 25132143 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod alone
Number of subjects: 228
Study 25132143 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 228
Study 22035976 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen/thrombin and autologous platelet hemostatic agent (standard hemostasis plus study product)
Number of subjects: 100
Study 22035976 — intervention group
Group type: COMPARATOR
Intervention: Standard hemostasis alone (control)
Number of subjects: 100
Study 19529944 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF MS)
Number of subjects: 0
Study 19529944 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision trees
Number of subjects: 0
Study 19529944 — intervention group
Group type: EXPERIMENTAL
Intervention: SELDI-TOF MS for beta-hCG-negative seminomas
Number of subjects: 0
Study 19529944 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 17611335 — intervention group
Group type: EXPERIMENTAL
Intervention: 10microg/kg fentanyl (Group A)
Number of subjects: 60
Study 17611335 — intervention group
Group type: EXPERIMENTAL
Intervention: 1microg/kg sufentanil (Group B)
Number of subjects: 60
Study 17611335 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5microg/kg sufentanil (Group C)
Number of subjects: 60
Study 17611335 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5microg/kg sufentanil (Group D)
Number of subjects: 60
Study 16130582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pram walking group (intervention)
Number of subjects: 60
Study 16130582 — intervention group
Group type: COMPARATOR
Intervention: Control group (not participating in pram walking group)
Number of subjects: 60
Study 12152252 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/day p.o. aspirin for 3 days
Number of subjects: 56
Study 12152252 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day p.o. aspirin for 3 days
Number of subjects: 56
Study 12152252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9917118 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 234
Study 9917118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 7549815 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of breast cancer risk education
Number of subjects: 395
Study 7549815 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (unmarried status)
Number of subjects: 395
Study 7549815 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level (high school or less)
Number of subjects: 395
Study 7549815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity (African American vs. White)
Number of subjects: 395
Study 7549815 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 395
Study 7549815 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression predictors
Number of subjects: 395
Study 30669202 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250mg/day + Budesonide nasal spray once a day
Number of subjects: 80
Study 30669202 — intervention group
Group type: COMPARATOR
Intervention: Budesonide nasal spray once a day
Number of subjects: 80
Study 28670911 — intervention group
Group type: COMPARATOR
Intervention: Exelon (reference)
Number of subjects: 40
Study 28670911 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (test)
Number of subjects: 40
Study 28670911 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine/Exelon
Number of subjects: 40
Study 25453593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 12 daily exposures to vegetable puree added to milk (days 1-12), then 12 x 2 daily exposures to vegetable puree added to rice (days 13-24)
Number of subjects: 36
Study 25453593 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - Plain milk and rice given, followed by 11 daily exposures to vegetable puree
Number of subjects: 36
Study 25453593 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received 11 daily exposures to vegetable puree after initial interventions
Number of subjects: 36
Study 23739785 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23% APF gel
Number of subjects: 60
Study 23739785 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study 21476457 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial video games
Number of subjects: 0
Study 21476457 — intervention group
Group type: COMPARATOR
Intervention: Violent video games
Number of subjects: 0
Study 19636603 — intervention group
Group type: EXPERIMENTAL
Intervention: Watercress extract (WCE) 0.1-10 microL/mL
Number of subjects: 0
Study 19636603 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenethyl isothiocyanate (PEITC) 1-10 microM
Number of subjects: 0
Study 19636603 — intervention group
Group type: EXPERIMENTAL
Intervention: Watercress consumption (85 g per day for 8 weeks)
Number of subjects: 0
Study 15497672 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Seralin)
Number of subjects: 24
Study 15497672 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 24
Study 15497672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 11580001 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained outpatient commitment (6 months or more)
Number of subjects: 0
Study 11580001 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot antipsychotics
Number of subjects: 0
Study 11580001 — intervention group
Group type: COMPARATOR
Intervention: Randomized control group
Number of subjects: 0
Study 11301561 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-albuterol 5 mg
Number of subjects: 15
Study 11301561 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-albuterol 1.25 mg
Number of subjects: 15
Study 11301561 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-albuterol
Number of subjects: 15
Study 11301561 — intervention group
Group type: EXPERIMENTAL
Intervention: (RS)-albuterol
Number of subjects: 15
Study 11301561 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-albuterol and (RS)-albuterol
Number of subjects: 15
Study 11301561 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-albuterol
Number of subjects: 15
Study 8148281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) 5 mg/kg/day
Number of subjects: 24
Study 8148281 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous reducing dose of CyA (1 mg/kg/day)
Number of subjects: 24
Study 8148281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fixed dose of CyA (5 mg/kg every fifth day)
Number of subjects: 24
Study 8148281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 24
Study 3211287 — intervention group
Group type: EXPERIMENTAL
Intervention: oral scopolamine 0.3 mg
Number of subjects: 20
Study 3211287 — intervention group
Group type: EXPERIMENTAL
Intervention: oral scopolamine 0.6 mg
Number of subjects: 20
Study 3211287 — intervention group
Group type: EXPERIMENTAL
Intervention: oral scopolamine 1.2 mg
Number of subjects: 20
Study 3211287 — intervention group
Group type: EXPERIMENTAL
Intervention: oral methylscopolamine 0.6 mg
Number of subjects: 20
Study 3211287 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 29754829 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 56
Study 29754829 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 56
Study 25942015 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-Hz WBV at higher amplitude (2-3 mm)
Number of subjects: 16
Study 25942015 — intervention group
Group type: COMPARATOR
Intervention: 40-Hz WBV at lower amplitude (1-2 mm)
Number of subjects: 16
Study 25942015 — intervention group
Group type: COMPARATOR
Intervention: No WBV (NV)
Number of subjects: 16
Study 25809183 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stem
Number of subjects: 60
Study 25809183 — intervention group
Group type: COMPARATOR
Intervention: Standard stem
Number of subjects: 60
Study 25809183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 23044919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid
Number of subjects: 28
Study 23044919 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline (control)
Number of subjects: 28
Study 20587350 — intervention group
Group type: EXPERIMENTAL
Intervention: Platycarya strobilacea fruit extract
Number of subjects: 0
Study 20587350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellagic acid
Number of subjects: 0
Study 20587350 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid
Number of subjects: 0
Study 20587350 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (P. strobilacea extract)
Number of subjects: 0
Study 20587350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18261569 — intervention group
Group type: EXPERIMENTAL
Intervention: Single low-dose anti-thymocyte globulin (ATG) prophylaxis (4-5 mg/kg)
Number of subjects: 68
Study 18261569 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy (cyclosporine, mycophenolate mofetil or azathioprine, and prednisolone)
Number of subjects: 68
Study 16096664 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan blue staining under air
Number of subjects: 52
Study 16096664 — intervention group
Group type: COMPARATOR
Intervention: Trypan blue staining under viscoelastic
Number of subjects: 52
Study 14743647 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose steroids (30 mg/kg/d of methylprednisolone for three to five days with a six-week taper)
Number of subjects: 0
Study 14743647 — intervention group
Group type: COMPARATOR
Intervention: Low-dose steroids
Number of subjects: 0
Study 14743647 — intervention group
Group type: COMPARATOR
Intervention: Steroids (general use)
Number of subjects: 0
Study 14743647 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment
Number of subjects: 0
Study 14743647 — intervention group
Group type: COMPARATOR
Intervention: Treatments studied in adults (applied to children with MS)
Number of subjects: 0
Study 14743647 — intervention group
Group type: COMPARATOR
Intervention: Recurrence of ADEM
Number of subjects: 0
Study 14743647 — intervention group
Group type: COMPARATOR
Intervention: Long-term outcome of childhood MS
Number of subjects: 0
Study 10817948 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguagraph (used for therapy and assessment)
Number of subjects: 0
Study 8899316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ukrain
Number of subjects: 10
Study 8899316 — intervention group
Group type: COMPARATOR
Intervention: Control (no Ukrain)
Number of subjects: 10
Study 1355149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg
Number of subjects: 10
Study 1355149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6096349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (500 mg) plus sulbactam (500 mg)
Number of subjects: 295
Study 6096349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (500 mg) plus metronidazole (1 g suppository)
Number of subjects: 295
Study 6096349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 6096349 — intervention group
Group type: EXPERIMENTAL
Intervention: Other types of operation
Number of subjects: 295
Study 6096349 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment groups (A + B)
Number of subjects: 295
Study 29619794 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness app usage for two weeks
Number of subjects: 78
Study 29619794 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no information about mobile apps)
Number of subjects: 78
Study 30388149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary diversity score of <4 food groups
Number of subjects: 389
Study 30388149 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group of 12-14 years
Number of subjects: 389
Study 30388149 — intervention group
Group type: EXPERIMENTAL
Intervention: Male children
Number of subjects: 389
Study 30388149 — intervention group
Group type: EXPERIMENTAL
Intervention: Households with medium wealth terciles
Number of subjects: 389
Study 30388149 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-enrolled in schools
Number of subjects: 389
Study 27269661 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-acting refrigerant topical agent (applied for 5 seconds)
Number of subjects: 30
Study 27269661 — intervention group
Group type: COMPARATOR
Intervention: 20% benzocaine gel topical (applied for 2 minutes)
Number of subjects: 30
Study 24983321 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin (SOF/RBV)
Number of subjects: 0
Study 21890591 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-37822681 at 5 mg
Number of subjects: 27
Study 21890591 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-37822681 at 10 mg
Number of subjects: 27
Study 21890591 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-37822681 at higher doses (15 mg and 20 mg)
Number of subjects: 27
Study 21890591 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-37822681 (various doses)
Number of subjects: 27
Study 21144971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive tailored PAD-specific counseling intervention
Number of subjects: 124
Study 21144971 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 124
Study 17386348 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril treatment for 2.5 years
Number of subjects: 36
Study 15446674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (Group-PK)
Number of subjects: 25
Study 15446674 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (Group-PN)
Number of subjects: 25
Study 15446674 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone (Group-P)
Number of subjects: 25
Study 11431653 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour myoglobin < or = 239 ng/mL
Number of subjects: 839
Study 11431653 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour troponin-I > 81.5 ng/mL
Number of subjects: 839
Study 11431653 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour CK-MB > 191 ng/mL
Number of subjects: 839
Study 11431653 — intervention group
Group type: COMPARATOR
Intervention: 12-hour myoglobin > 239 ng/mL
Number of subjects: 839
Study 11431653 — intervention group
Group type: COMPARATOR
Intervention: 12-hour troponin-I < or = 81.5 ng/mL
Number of subjects: 839
Study 11431653 — intervention group
Group type: COMPARATOR
Intervention: 12-hour CK-MB < or = 191 ng/mL
Number of subjects: 839
Study 9672343 — intervention group
Group type: EXPERIMENTAL
Intervention: Single hyperphosphate enema 1 h before the procedure
Number of subjects: 164
Study 9672343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperphosphate enema given 1 and 2 h before the procedure
Number of subjects: 164
Study 9672343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperphosphate enema administered 1 and 2 h before the procedure, preceded by a 296 ml bottle of magnesium citrate taken p.o. the night before
Number of subjects: 164
Study 7974313 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate 50 micrograms twice daily
Number of subjects: 427
Study 7974313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 2690316 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201-995 (200 micrograms, subcutaneously, 1 ml, three times within 16 hours)
Number of subjects: 6
Study 2690316 — intervention group
Group type: COMPARATOR
Intervention: Isotone saline (control, subcutaneously, 1 ml, three times within 16 hours)
Number of subjects: 6
Study 779797 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 0
Study 779797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30654697 — intervention group
Group type: EXPERIMENTAL
Intervention: EmoBio
Number of subjects: 83
Study 30654697 — intervention group
Group type: COMPARATOR
Intervention: Cognitive measures (MCCB and WAIS-IV)
Number of subjects: 83
Study 27918396 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized PALs (Rodenstock Impression FreeSign 3)
Number of subjects: 51
Study 27918396 — intervention group
Group type: COMPARATOR
Intervention: Conventional PALs (Rodenstock Progressiv Life Free)
Number of subjects: 51
Study 25738850 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101 (2 mg/cm2, total dose 100 mg)
Number of subjects: 24
Study 24582846 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-elbow cast excluding the thumb
Number of subjects: 62
Study 24582846 — intervention group
Group type: COMPARATOR
Intervention: Below-elbow cast including the thumb
Number of subjects: 62
Study 24582846 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 21733283 — intervention group
Group type: EXPERIMENTAL
Intervention: D-serine (DSR) 30 mg/kg.d
Number of subjects: 10
Study 19117329 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based multi-behavior intervention focused on exercise and a low saturated fat, plant-based diet
Number of subjects: 641
Study 19117329 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based multi-behavior intervention
Number of subjects: 641
Study 17322163 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-directed patient education (EDU group)
Number of subjects: 114
Study 17322163 — intervention group
Group type: COMPARATOR
Intervention: Routine medical and nursing care (No EDU group)
Number of subjects: 114
Study 15073698 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative heparin therapy (POHI group)
Number of subjects: 46
Study 15073698 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONT)
Number of subjects: 46
Study 11576496 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconsultation (teleneurology)
Number of subjects: 168
Study 11576496 — intervention group
Group type: COMPARATOR
Intervention: Conventional consultation
Number of subjects: 168
Study 11576496 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of costs
Number of subjects: 168
Study 9589675 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) therapy (approximately 0.22 IU/kg.week) for 24 months
Number of subjects: 18
Study 7604796 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin monotherapy (40 mg/day)
Number of subjects: 147
Study 7604796 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin monotherapy (30.2 mg/day)
Number of subjects: 147
Study 7604796 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (39.3 mg/day) plus cholestyramine (10.3 mg/day)
Number of subjects: 147
Study 7604796 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin monotherapy (32.5 mg/day)
Number of subjects: 147
Study 7604796 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin monotherapy
Number of subjects: 147
Study 2191507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nifedipine (0.8-1.0 mg)
Number of subjects: 29
Study 2191507 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, n = 8)
Number of subjects: 29
Study 506972 — intervention group
Group type: EXPERIMENTAL
Intervention: Continental type breakfast served with coffee (standardized against reference dose of 3 mg Fe from derrous ascorbate)
Number of subjects: 129
Study 506972 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast with tea
Number of subjects: 129
Study 506972 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast with orange juice
Number of subjects: 129
Study 30529583 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 81
Study 30529583 — intervention group
Group type: COMPARATOR
Intervention: Placebo enemas
Number of subjects: 81
Study 28164407 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP‐NLX taper
Number of subjects: 125
Study 25510446 — intervention group
Group type: EXPERIMENTAL
Intervention: 70‐kVp and CM 64 mL
Number of subjects: 69
Study 25510446 — intervention group
Group type: EXPERIMENTAL
Intervention: 70‐kVp and CM 40 mL
Number of subjects: 69
Study 25510446 — intervention group
Group type: COMPARATOR
Intervention: 120‐kVp and CM 64 mL
Number of subjects: 69
Study 25307707 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml ropivacaine 7.5 mg/ml (R group)
Number of subjects: 50
Study 25307707 — intervention group
Group type: COMPARATOR
Intervention: Saline (C group)
Number of subjects: 50
Study 22050141 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of peginterferon alfa-2a plus ribavirin
Number of subjects: 236
Study 22050141 — intervention group
Group type: COMPARATOR
Intervention: 48 weeks of peginterferon alfa-2a plus ribavirin
Number of subjects: 236
Study 22050141 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 weeks of peginterferon alfa-2a plus ribavirin
Number of subjects: 236
Study 22050141 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 weeks of peginterferon alfa-2a plus ribavirin
Number of subjects: 236
Study 19470469 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 17617808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg once daily
Number of subjects: 621
Study 17617808 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 400 microg once daily
Number of subjects: 621